Bi-lateral HGN Therapy in Real-World Patients -Post Approval Research Investigation
A legfontosabb adatok
- Ki végzi
- Nyxoah Inc.
- Hol
- Miami és Summit (Egyesült Államok)Mind a 2 helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 229 fő, tervezett
- Kezdés
- 2026. jún.
- Várható befejezés
- 2032. okt.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1
- A regiszteradat frissítve
- 2026. június 22.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with moderate to severe obstructive sleep apnea (breathing stops during sleep) who could not use, did not tolerate or refused PAP (air pressure mask) treatment. Everyone gets the Genio® System 2.1 implant.
- Életkor
- 22 years and older; people above 75 years cannot join.
- Nem
- All sexes
- A betegség stádiuma
- Moderate to severe obstructive sleep apnea, with an apnea-hypopnea index (AHI, breathing pauses per hour) from 15 to 65. It must be measured on a full-night sleep study (PSG) done no earlier than 2 years before enrollment.
- Korábbi kezelés
- Standard treatments for moderate to severe OSA must have failed or not been tolerated, or the person cannot have them.
- Biomarker vagy leletérték
- A Drug-Induced Sleep Endoscopy (DISE, a camera check of the airway during medicine-induced sleep) result from no earlier than 2 years before enrollment.
A részvétel fő kizáró okai
- Central and mixed apneas make up 25% or more of the total AHI.
- Body Mass Index (BMI) above 32 kg/m2, or Complete Concentric Collapse (CCC, the airway closing all around) at the soft palate.
- An implanted device that may interact with the Genio® System 2.1.
- Pregnant, planning pregnancy or breastfeeding.
- A condition or procedure that has harmed nerve control of the upper airway.
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- Have an apnea-hypopnea index (AHI) greater than or equal to 15 and less than or equal to 65, measured on a full-night PSG performed no earlier than 2 years prior to enrollment (AHI4 and ODI4 available)
- Be adults 22 years of age and older
- Have been confirmed to have failed, not tolerated, or be ineligible to be treated with current standard of care treatments for moderate to severe OSA
- Have pursued insurance pre-authorization for Genio® Therapy, recognizing that pre-authorization does not ensure payment, or demonstrate willingness to assume any out-of-pocket costs. The sponsor will not be responsible for treatment-related charges
- Agree to participate in the study and voluntarily sign and date an informed consent form
- Be willing and capable of complying with all study requirements, including specific lifestyle considerations, performing all follow-up visits, evaluation procedures and questionnaires for the whole duration of the trial
- Have a result of a Drug- Induced Sleep Endoscopy (DISE), no earlier than 2 years prior to enrollment
Ki nem vehet részt
- Any functional or structural problem, medical illness or condition that would prevent or interfere with implantation, activation or continued use of the Genio® Therapy
- Any condition or procedure that has compromised neurological control of the upper airway
- Be part of the populations for which the safety and effectiveness of the Genio® System 2.1 has not been fully assessed:; Patients below 22 or above 75 years of age; Patients with a Body Mass Index (BMI) above 32 kg/m2; Patients with an Apnea Hypopnea Index (AHI) below 15 or over 65 events/hr; Patients with Complete Concentric Collapse (CCC) at the soft palate level
- Combined central and mixed apnea-hypopnea index (AHI) greater than or equal to 25% of the total AHI
- Have an implantable device which may be susceptible to unintended interaction with the Genio® System 2.1
- Women who are pregnant, planning to become pregnant or breastfeeding
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- PharmaDev Clinical Research Institute, LLCMiami, Egyesült ÁllamokContact: Olivia Falcon ValdesRésztvevőt keres
- Nyxoah, IncSummit, Egyesült ÁllamokContact: Lorin PetreToborzás még nem indult
A vizsgálatról
Mit akar kideríteni a vizsgálat
The objective of the BREATHE study is to demonstrate the continued safety and effectiveness of the Genio® System in treating subjects diagnosed with moderate to severe obstructive sleep apnea (OSA) who are intolerant to or failed/refused PAP treatments.
A vizsgálat csoportja
- Genio System 2.1
This is a single-arm study. All consented and eligible subjects will be implanted with the Genio 2.1 System.
Kezelés: This is a single arm study, all consented and eligible subjects will be implanted with the Genio® System 2.1
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. június 22.